Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NORFLEX vs BACLOFEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Orphenadrine is a centrally acting skeletal muscle relaxant with anticholinergic and local anesthetic properties. It acts primarily by blocking cholinergic receptors in the central nervous system, particularly in the reticular activating system, leading to reduced muscle spasm and rigidity.
GABA-B receptor agonist; inhibits monosynaptic and polysynaptic spinal reflexes by hyperpolarizing afferent terminals.
Adjunctive therapy for acute musculoskeletal conditions associated with painful muscle spasm,Off-label: Treatment of Parkinsonism and drug-induced extrapyramidal reactions
Spasticity due to multiple sclerosis (FDA approved),Spinal cord injury (FDA approved),Intrathecal use for severe spasticity of cerebral origin (off-label),Hiccups (off-label),Alcohol withdrawal syndrome (off-label),Trigeminal neuralgia (off-label)
Adults: 100 mg orally twice daily. Maximum dose: 200 mg/day.
Initial: 5 mg orally 3 times daily; increase by 5 mg per dose every 3 days to max 80 mg/day (20 mg 4 times daily). Intrathecal: initial test dose 50-100 mcg; for continuous infusion, daily dose typically 300-800 mcg.
Terminal elimination half-life: 15-20 hours. Clinical context: Allows twice-daily dosing; steady-state reached in 3-5 days.
Terminal half-life: 2.5-4 hours (young adults), 4-8 hours (elderly); clinical context: requires frequent dosing for spasticity.
Primarily hepatic via cytochrome P450 enzymes, including CYP2D6 and CYP3A4; undergoes N-demethylation and hydroxylation.
Metabolized via hepatic deamination by transaminase; primarily excreted unchanged in urine (approximately 70-80%), with minor hepatic metabolism.
Renal: ~50% as unchanged drug and metabolites; biliary/fecal: ~40% as metabolites; <10% unchanged in feces.
Renal: 70-80% unchanged; fecal: <5%; biliary: minimal.
~90% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
30-35% bound to albumin.
Vd: 2-3 L/kg (150-210 L for 70 kg adult). Indicates extensive tissue distribution.
Vd: 0.5-0.7 L/kg; indicates distribution into total body water.
Oral: 85-90% (first-pass metabolism minimal).
Oral: 70-85% with high variability; intrathecal: 100%.
GFR 30-50 m L/min: 50 mg twice daily. GFR <30 m L/min: Not recommended.
Cr Cl 30-50 m L/min: reduce dose by 50%; Cr Cl <30 m L/min: avoid use or use with extreme caution, reduce dose by 75%.
Child-Pugh A: 50 mg twice daily; Child-Pugh B: 50 mg once daily; Child-Pugh C: Contraindicated.
No specific guidelines; use with caution due to potential for increased sedation/neurotoxicity.
Not recommended for patients under 12 years. Safety and efficacy not established.
Children 2-7 years: initial 2.5 mg orally 4 times daily, increase by 2.5 mg/dose every 3 days to max 40 mg/day; children ≥8 years: initial 5 mg orally 3 times daily, increase as in adults to max 60 mg/day.
Initiate at 50 mg twice daily. Monitor for anticholinergic effects and cognitive impairment.
Start at low end of dosing range (5 mg twice daily), titrate slowly due to increased risk of sedation, weakness, and cognitive impairment.
None
Abrupt discontinuation may cause withdrawal symptoms including hallucinations, seizures, and life-threatening hyperpyrexia; taper dose gradually.
May impair mental alertness and physical coordination; caution in activities requiring alertness.,Anticholinergic effects: caution in patients with glaucoma, prostatic hypertrophy, or urinary retention.,Use with caution in elderly patients due to increased sensitivity to anticholinergic effects.,May precipitate tachycardia or transient syncope in patients with cardiac disorders.,Hepatic impairment: monitor liver function; dose adjustment may be needed.
May cause CNS depression (drowsiness, sedation) and impair ability to drive or operate machinery.,Risk of withdrawal syndrome including fever, altered mental status, and autonomic instability upon abrupt cessation.,Use with caution in patients with renal impairment; dose adjustment required.,May exacerbate psychiatric disorders; monitor for hallucinations, confusion.,Risk of respiratory depression when combined with other CNS depressants.
Hypersensitivity to orphenadrine or any component of the formulation,Glaucoma, particularly narrow-angle glaucoma,Gastrointestinal obstruction, paralytic ileus, or myasthenia gravis,Prostatic hypertrophy or bladder neck obstruction with urinary retention,Concurrent use with propoxyphene (risk of confusion, anxiety, tremors)
Hypersensitivity to baclofen.,Intrathecal formulation is contraindicated in patients with active infection or bleeding disorders at lumbar puncture site.,Women who are breastfeeding (relative contraindication).
No specific food interactions. Avoid alcohol as it may increase CNS depression. Grapefruit juice has not been reported to interact with orphenadrine.
No specific food interactions. Avoid alcohol due to additive CNS depression.
Insufficient human data; animal studies show no fetal harm. First trimester: theoretical risk, avoid if possible. Second/third trimesters: no known malformations. Risk of uterine inertia and neonatal respiratory depression if used near term.
First trimester: Limited human data; animal studies show increased fetal malformations (omphalocele, exencephaly) at doses equivalent to human therapeutic range. Second and third trimesters: Risk of neonatal withdrawal (hypertonia, seizures) with chronic maternal use. Avoid unless benefit outweighs risk.
Orphenadrine is excreted in breast milk in small amounts; M/P ratio not established. Reports of infant drowsiness. Caution advised, especially with higher doses or prolonged use.
Baclofen excreted into breast milk in low concentrations (M/P ratio approximately 0.43). Relative infant dose estimated 0.9% of maternal weight-adjusted dose. Considered compatible with breastfeeding, but monitor infant for sedation and hypotonia.
No specific dose adjustments for pregnancy due to limited data. Use lowest effective dose. Pharmacokinetics may be altered due to increased volume of distribution and clearance, but no formal studies.
No specific dose adjustments recommended. Increased renal blood flow and GFR in pregnancy may reduce baclofen levels; monitor clinical effect and adjust dose as needed. Avoid abrupt discontinuation due to risk of maternal withdrawal and rebound spasticity.
NORFLEX (orphenadrine citrate) is a centrally acting skeletal muscle relaxant with anticholinergic properties. It is used as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute painful musculoskeletal conditions. Clinical pearls: 1) Onset of action is rapid (within 1 hour) with a duration of 4-6 hours; 2) Avoid in patients with glaucoma, prostatic hypertrophy, or myasthenia gravis due to anticholinergic effects; 3) May cause drowsiness and blurred vision; caution patients about driving; 4) Not recommended for use in children under 12; 5) Drug interactions: additive anticholinergic effects with other anticholinergics, CNS depression with alcohol or other CNS depressants.
Abrupt withdrawal can cause severe rebound spasticity, fever, and rhabdomyolysis; taper by 5-10 mg/week. Intrathecal baclofen pumps require careful monitoring for overdose (respiratory depression) or withdrawal. Use with caution in renal impairment (dose adjust for Cr Cl <30 m L/min).
Take exactly as prescribed; do not increase dose or frequency.,May cause drowsiness, dizziness, or blurred vision; avoid driving or operating machinery until you know how this medication affects you.,Avoid alcohol and other CNS depressants (e.g., sedatives, tranquilizers) as they may increase drowsiness.,Dry mouth is common; suck on hard candy or ice chips for relief.,Report promptly: difficulty urinating, eye pain, rapid heartbeat, or confusion.,Do not stop suddenly; withdrawal symptoms may occur.,Store at room temperature, away from moisture and heat.
Do not stop taking baclofen suddenly; sudden discontinuation can cause serious withdrawal symptoms including hallucinations, seizures, and high fever.,Avoid alcohol and CNS depressants as they increase sedation and risk of falls.,May cause dizziness or drowsiness; avoid driving or operating machinery until you know how it affects you.,Take exactly as prescribed; missed doses can lead to muscle spasms or withdrawal.,Report any unusual muscle stiffness, rapid heart rate, or dark urine immediately.
No interactions on record
"Sevoflurane enhances the inhibitory effects of baclofen on the central nervous system by potentiating GABA-B receptor activity, leading to an increased risk of profound sedation, respiratory depression, and hypotension. This synergistic interaction can result in prolonged recovery from anesthesia and the need for ventilatory support. Clinically, patients may exhibit exaggerated muscle relaxation and a delayed emergence from anesthesia, particularly at higher doses of either agent."
"Concomitant use of etidocaine, an amide-type local anesthetic that blocks voltage-gated sodium channels, and baclofen, a GABAB receptor agonist used for muscle spasticity, may lead to additive central nervous system (CNS) depression and respiratory depression. This interaction results from synergistic depressant effects on the brainstem and spinal cord, increasing the risk of sedation, dizziness, ataxia, and impaired consciousness. Clinically, patients may experience excessive drowsiness, respiratory compromise, and impaired motor coordination, particularly in the elderly or those with pre-existing renal impairment where baclofen accumulation is more likely."
"The coadministration of Baclofen and Metaxalone results in additive central nervous system (CNS) depression due to their shared pharmacodynamic effects on GABAergic and sedative pathways. This combination can potentiate sedation, dizziness, ataxia, and respiratory depression, particularly in elderly patients or those with renal impairment. Clinical outcomes may include increased risk of falls, cognitive impairment, and impaired motor coordination, necessitating cautious dose titration."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NORFLEX vs BACLOFEN, answered by our medical review team.
NORFLEX is a Muscle Relaxant that works by Orphenadrine is a centrally acting skeletal muscle relaxant with anticholinergic and local anesthetic properties. It acts primarily by blocking cholinergic receptors in the central nervous system, particularly in the reticular activating system, leading to reduced muscle spasm and rigidity.. BACLOFEN is a Skeletal Muscle Relaxant that works by GABA-B receptor agonist; inhibits monosynaptic and polysynaptic spinal reflexes by hyperpolarizing afferent terminals.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NORFLEX and BACLOFEN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NORFLEX is: Adults: 100 mg orally twice daily. Maximum dose: 200 mg/day.. The standard adult dose of BACLOFEN is: Initial: 5 mg orally 3 times daily; increase by 5 mg per dose every 3 days to max 80 mg/day (20 mg 4 times daily). Intrathecal: initial test dose 50-100 mcg; for continuous infusion, daily dose typically 300-800 mcg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NORFLEX and BACLOFEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NORFLEX is classified as Category C. Insufficient human data; animal studies show no fetal harm. First trimester: theoretical risk, avoid if possible. Second/third trimesters: no known malformations. Risk of uterine i. BACLOFEN is classified as Category C. First trimester: Limited human data; animal studies show increased fetal malformations (omphalocele, exencephaly) at doses equivalent to human therapeutic range. Second and third t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.